INCY vs SNDX

Incyte (INCY) is a well-established large-cap biopharmaceutical company ($19.90B market cap) with a strong portfolio, notably Jakafi and Opzelura, and a diversified pipeline. While it demonstrates solid fundamentals, consistent revenue growth, and potential for sustained, incremental expansion through pipeline advancements and label extensions, its current size and operational maturity render a 10...

Syndax Pharmaceuticals maintains an exceptional 10x growth potential, largely de-risked by the recent FDA approval of revumenib for R/R KMT2A-rearranged AML/ALL. This first-in-class menin inhibitor targets a high-value, unmet need, establishing a clear path to market leadership in this oncology niche. Axatilimab, approved in 2024 and partnered with Incyte, provides a foundational revenue stream, b...